These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18794099)

  • 1. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.
    Personeni N; Fieuws S; Piessevaux H; De Hertogh G; De Schutter J; Biesmans B; De Roock W; Capoen A; Debiec-Rychter M; Van Laethem JL; Peeters M; Humblet Y; Van Cutsem E; Tejpar S
    Clin Cancer Res; 2008 Sep; 14(18):5869-76. PubMed ID: 18794099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.
    Li YH; Wang F; Shen L; Deng YM; Shao Q; Feng F; An X; Wang FH; Wang ZQ; Xu RH; Shao JY
    Clin Cancer Res; 2011 Jan; 17(2):382-90. PubMed ID: 20884623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number.
    Italiano A; Follana P; Caroli FX; Badetti JL; Benchimol D; Garnier G; Gugenheim J; Haudebourg J; Keslair F; Lesbats G; Lledo G; Roussel JF; Pedeutour F; François E
    Ann Surg Oncol; 2008 Feb; 15(2):649-54. PubMed ID: 17987340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab.
    Campanella C; Mottolese M; Cianciulli A; Torsello A; Merola R; Sperduti I; Melucci E; Conti S; Diodoro MG; Zeuli M; Paoletti G; Cognetti F; Garufi C
    J Transl Med; 2010 Apr; 8():36. PubMed ID: 20398370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.
    Sartore-Bianchi A; Moroni M; Veronese S; Carnaghi C; Bajetta E; Luppi G; Sobrero A; Barone C; Cascinu S; Colucci G; Cortesi E; Nichelatti M; Gambacorta M; Siena S
    J Clin Oncol; 2007 Aug; 25(22):3238-45. PubMed ID: 17664472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.
    Scartozzi M; Bearzi I; Mandolesi A; Pierantoni C; Loupakis F; Zaniboni A; Negri F; Quadri A; Zorzi F; Galizia E; Berardi R; Biscotti T; Labianca R; Masi G; Falcone A; Cascinu S
    BMC Cancer; 2009 Aug; 9():303. PubMed ID: 19712476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer.
    Birkman EM; Avoranta T; Ålgars A; Korkeila E; Lintunen M; Lahtinen L; Kuopio T; Ristamäki R; Carpén O; Sundström J
    Hum Pathol; 2018 Dec; 82():163-171. PubMed ID: 30096327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis.
    Jiang Z; Li C; Li F; Wang X
    PLoS One; 2013; 8(2):e56205. PubMed ID: 23441167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
    Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
    J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis.
    Yang ZY; Shen WX; Hu XF; Zheng DY; Wu XY; Huang YF; Chen JZ; Mao C; Tang JL
    J Hematol Oncol; 2012 Aug; 5():52. PubMed ID: 22897982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy.
    Ålgars A; Avoranta T; Österlund P; Lintunen M; Sundström J; Jokilehto T; Ristimäki A; Ristamäki R; Carpén O
    PLoS One; 2014; 9(6):e99590. PubMed ID: 24940619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
    Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
    Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.
    Kwak Y; Yun S; Nam SK; Seo AN; Lee KS; Shin E; Oh HK; Kim DW; Kang SB; Kim WH; Lee HS
    J Transl Med; 2017 Aug; 15(1):167. PubMed ID: 28764718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer.
    Ålgars A; Lintunen M; Carpén O; Ristamäki R; Sundström J
    Br J Cancer; 2011 Jul; 105(2):255-62. PubMed ID: 21694725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
    Chung CH; Ely K; McGavran L; Varella-Garcia M; Parker J; Parker N; Jarrett C; Carter J; Murphy BA; Netterville J; Burkey BB; Sinard R; Cmelak A; Levy S; Yarbrough WG; Slebos RJ; Hirsch FR
    J Clin Oncol; 2006 Sep; 24(25):4170-6. PubMed ID: 16943533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
    Lièvre A; Bachet JB; Le Corre D; Boige V; Landi B; Emile JF; Côté JF; Tomasic G; Penna C; Ducreux M; Rougier P; Penault-Llorca F; Laurent-Puig P
    Cancer Res; 2006 Apr; 66(8):3992-5. PubMed ID: 16618717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
    Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
    N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
    Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
    J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?
    Sauer T; Guren MG; Noren T; Dueland S
    Histopathology; 2005 Dec; 47(6):560-4. PubMed ID: 16324192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.
    Cappuzzo F; Finocchiaro G; Rossi E; Jänne PA; Carnaghi C; Calandri C; Bencardino K; Ligorio C; Ciardiello F; Pressiani T; Destro A; Roncalli M; Crino L; Franklin WA; Santoro A; Varella-Garcia M
    Ann Oncol; 2008 Apr; 19(4):717-23. PubMed ID: 17974556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.